Rare Biomarkers Specimen Collection and Stabilization Market

Rare Biomarkers Specimen Collection And Stabilization Market Research, 2031

The global Rare Biomarkers Specimen Collection And Stabilization Market Size was valued at $23.3 billion in 2021, and is projected to reach $54.2 billion by 2031, growing at a CAGR of 8.7% from 2022 to 2031.A biomarker is a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. A biomarker can be any biological indicator that can be measured. For instance, biomarkers can be cellular or molecular (DNA, RNA, protein, metabolites). They are measured from a tissue biopsy or a liquid biopsy (blood, urine, saliva). Other biomarkers (physiological, morphological, etc.) can be also used or measured through clinical or medical imaging. It can be either quantitative or qualitative. Qualitative biomarkers could be involved in a pathogenic process detection within a yes/no analysis, while quantitative biomarkers are involved in pathogenic process detection with a threshold effect. The biomarkers are used in research and clinical practice for various purposes, such as for the diagnosis of diseases or predicting risks of disease, monitoring healthy people to detect early signs of disease, determining whether a treatment is efficient or not, targeting specific groups of people for whom a particular drug may be useful, producing safer drugs by predicting the potential for adverse effects earlier and providing researchers with the opportunity of having a global view of the events and changes that are always occurring within a cell.

The overall impact of COVID-19 remains positive on rare biomarkers specimen collection and stabilization market. Owing to increase in the prevalence of rare diseases and rising geriatric population. Moreover, rising innovations in diagnostic of disease using biomarkers and increase in the demand for isolation kits and reagents boost the market growth. The ongoing pandemic of coronavirus disease 2019 (COVID-19) poses several challenges to clinicians. Timely diagnosis and hospitalization, risk stratification, effective utilization of intensive care services, selection of appropriate therapies, monitoring and timely discharge are essential to save the maximum number of lives. Clinical assessment is indispensable, but laboratory markers, or biomarkers, can provide additional, objective information which can significantly impact these components of patient care. COVID-19 is not a localized respiratory infection but a multisystem disease caused by a diffuse systemic process involving a complex interplay of the immunological, inflammatory and coagulative cascades. The understanding of what the virus does to the body and how the body reacts to it has uncovered a gamut of potential biomarkers.

The key factors that drive Rare Biomarkers Specimen Collection And Stabilization Market Growth are the rise in prevalence of rare and genetic disorders such as cystic fibrosis, muscular dystrophy, spina bifida and various others, increasing preference for minimally non-invasive mode of disease treatment, increasing demand for personalized medicine, and the rise of a geriatric population. For instance, in May, 2022 Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) comprehensive (EU) test. This single test kit, launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. Moreover, increased R&D activities for the launch of approved novel drugs on rare diseases, favorable government reimbursement policies for rare biomarkers, increased investment in the modern healthcare facility sector, and increased demand for accurate chronic disease diagnosis are anticipated to fuel the market growth.

However, the tedious and lengthy process for the development of biomarker and high cost of the development hampers the market growth. Conversely, emerging healthcare market in developing countries, increase in applications of rare biomarker specimens in pharmacogenomics and increase in the risk of pandemic and rare genetic diseases is expected to provide the lucrative Rare Biomarkers Specimen Collection And Stabilization Market Opportunity during the forecast period. 

The rare biomarkers specimen collection and stabilization market is segmented on the basis of type, product, application, and region. By type the market is segmented into circulating cell free DNA, circulating tumor cells and exosomes vesicles. By product the market is segmented into isolation kits & reagents, blood collection tubes and systems. By application, the market is segmented into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases and other. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. By application, on the basis of oncology, the market is further sub-segmented into research and diagnostics.

Type Segment review

By type, the rare biomarkers specimen collection and stabilization market is segmented into circulating cell free DNA, circulating tumor cells and exosomes vesicles. In 2021, the circulating cell free DNA segment accounted for the largest share of the market. The dominance of this segment can be attributed tothe  increasing adoption of NIPT in detecting chromosomal anomalies in the fetus and as it is a very promising tumor biomarker for cancer diagnosis and monitoring, prognosis assessment, and personalized medication guidance.

The circulating tumor cells segment is anticipated to grow at a significant rate during the forecast period. Owing to recent advancement in circulating tumor cells (CTC) isolation and ex vivo culture techniques facilitate single-cell omics and the development of related animal models to study CTC-mediated metastatic progression which drives the growth of rare biomarkers specimen collection and stabilization market.

Product Segment Review

By product, the market is segmented into isolation kits & reagents, blood collection tubes and systems. In 2021, the isolation kits & reagents segment accounted for the largest Rare Biomarkers Specimen Collection And Stabilization Market Share. The dominance of this segment can be attributed to rise in the prevalence of cancer and rare genetic disorder and the increase in investment for exploring the utility of CTCs in diagnosis, prognosis, and treatment monitoring are the key factors that drives the growth ofthe  market in upcoming years.

The blood collection tubes segment are expected to witness considerable market growth during the forecast period, owing to the rise in the geriatric population and the increase in the prevalence of cancer and other chronic diseases which has increased the demand for blood collection tubes for the collection of samples to diagnose lethal and other genetic diseases.

Application Segment Review

By application the rare biomarkers specimen collection and stabilization market is segmented into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases and others. The oncology segment exhibited the highest growth in 2021, and is anticipated to lead during the forecast period, owing to increase in advancement in technology coupled with an increased interest in personalized medication have led to the rapid expansion of precision medicine in oncology and rise in the prevalence of cancer cases around the globe.

The cardiovascular disease segment is anticipated to grow at a significant rate during the forecast period. Owing to the rise in the prevalence of cardiovascular diseases which increases the demand for the development of novel drug therapies using biomarkers.

Region Segment Review

Region wise, the rare biomarkers specimen collection and stabilization market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a majority of the rare biomarker’s specimen collection and stabilization market share in 2021 and is anticipated to remain dominant during the forecast period. The market is mainly driven by the rising prevalence of chronic and genetic diseases, an increase in healthcare expenditure, increase in the number of approved rare biomarker isolation kits for both clinical and research use is anticipated to increase the usage of liquid biopsy and assisted reproductive technology space in the region which drives the Rare Biomarkers Specimen Collection And Stabilization Market Size in the forecast period.

Asia-Pacific was the second largest contributor to the Rare Biomarkers Specimen Collection And Stabilization Industry in 2021, and is expected to register the fastest CAGR during the forecast period. This is due to the presence of high unmet medical needs and constantly improving healthcare infrastructure to cure chronic disorders. In addition, increasing investment for exploring the utility of circulating tumor cells (CTCs) in diagnosis, prognosis, and treatment monitoring has provided lucrative growth opportunities to players involved in the developing marketing will further contribute to the growth of the market.

The key players that operate in the rare biomarkers specimen collection and stabilization market are Agilent Technologies, Bio-Rad Laboratories inc., Charles River Laboratories Inc, F. Hoffman La Roche AG, Merck KGaA, Miltenyi Biotec, Perkin Elmer, Qiagen, Thermofisher Scientific Inc and Siemens AG.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rare biomarkers specimen collection and stabilization market analysis from 2021 to 2031 to identify the prevailing rare biomarkers specimen collection and stabilization market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the rare biomarkers specimen collection and stabilization market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global rare biomarkers specimen collection and stabilization market trends, key players, market segments, application areas, and market growth strategies.

 Rare Biomarkers Specimen Collection and Stabilization Market Report Highlights